Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Aug 27;62(9):e00275-18.
doi: 10.1128/AAC.00275-18. Print 2018 Sep.

Pharmacokinetics and Comprehensive Analysis of the Tissue Distribution of Eravacycline in Rabbits

Affiliations

Pharmacokinetics and Comprehensive Analysis of the Tissue Distribution of Eravacycline in Rabbits

Vidmantas Petraitis et al. Antimicrob Agents Chemother. .

Abstract

Eravacycline (7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline or TP-434) is a novel, fully synthetic broad-spectrum fluorocycline with potent activity against Gram-positive bacteria, anaerobes, and multidrug-resistant Enterobacteriaceae We characterized the plasma pharmacokinetics of eravacycline and conducted a comprehensive analysis of the eravacycline tissue distribution in rabbits after multiple-day dosing. For single-dose pharmacokinetic analysis, eravacycline was administered to New Zealand White (NZW) rabbits at 1, 2, 4, 8, and 10 mg/kg of body weight intravenously (i.v.) once a day (QD) (n = 20). For multidose pharmacokinetic analysis, eravacycline was administered at 0.5, 1, 2, and 4 mg/kg i.v. QD (n = 20) for 6 days. Eravacycline concentrations in plasma and tissues were analyzed by a liquid chromatography-tandem mass spectrometry assay. Mean areas under the concentration-time curves (AUCs) following a single eravacycline dose ranged from 5.39 μg · h/ml to 183.53 μg · h/ml. Within the multidose study, mean AUCs ranged from 2.53 μg · h/ml to 29.89 μg · h/ml. AUCs correlated linearly within the dosage range (r = 0.97; P = 0.0001). In the cardiopulmonary system, the concentrations were the highest in the lung, followed by the heart > pulmonary alveolar macrophages > bronchoalveolar lavage fluid; for the intra-abdominal system, the concentrations were the highest in bile, followed by the liver > gallbladder > spleen > pancreas; for the renal system, the concentrations were the highest in urine, followed by those in the renal cortex > renal medulla; for the musculoskeletal tissues, the concentrations were the highest in muscle psoas, followed by those in the bone marrow > adipose tissue; for the central nervous system, the concentrations were the highest in cerebrum, followed by those in the aqueous humor > cerebrospinal fluid > choroid > vitreous. The prostate and seminal vesicles demonstrated relatively high mean concentrations. The plasma pharmacokinetic profile of 0.5 to 4 mg/kg in NZW rabbits yields an exposure comparable to that in humans (1 or 2 mg/kg every 12 h) and demonstrates target tissue concentrations in most sites.

Keywords: eravacycline; pharmacokinetics; rabbits; tissue distribution.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Plasma pharmacokinetics of eravacycline after intravenous administration of a single dose to healthy New Zealand White rabbits.
FIG 2
FIG 2
Eravacycline plasma AUC-versus-dose correlation. Correlations were determined by the use of Spearman's rank correlation after administration of a single dose (A) and multiple doses (B). Dotted lines represent 95% confidence intervals.
FIG 3
FIG 3
Plasma pharmacokinetics of eravacycline after intravenous administration of multiple doses to healthy New Zealand White rabbits.
FIG 4
FIG 4
Distribution of eravacycline after intravenous multiple dosing to healthy New Zealand White rabbits in cardiopulmonary tissue/fluid. For the assessment of tissue concentrations of eravacycline, samples were collected on day 7, 1 h after last infusion. All values are expressed as mean ± SEM.
FIG 5
FIG 5
Distribution of eravacycline after intravenous multiple dosing to healthy New Zealand White rabbits in intraabdominal tissue/fluid. For the assessment of tissue concentrations of eravacycline, samples were collected on day 7, 1 h after last infusion. All values are expressed as mean ± SEM.
FIG 6
FIG 6
Distribution of eravacycline after intravenous multiple dosing to healthy New Zealand White rabbits in renal tissue/fluid. For the assessment of tissue concentrations of eravacycline, samples were collected on day 7, 1 h after last infusion. All values are expressed as mean ± SEM.
FIG 7
FIG 7
Distribution of eravacycline after intravenous multiple dosing to healthy New Zealand White rabbits in musculoskeletal tissue. For the assessment of tissue concentrations of eravacycline, samples were collected on day 7, 1 h after last infusion. All values are expressed as mean ± SEM.
FIG 8
FIG 8
Distribution of eravacycline after intravenous multiple dosing to healthy New Zealand White rabbits in CNS tissue/fluid. For the assessment of tissue concentrations of eravacycline, samples were collected on day 7, 1 h after last infusion. All values are expressed as mean ± SEM.
FIG 9
FIG 9
Distribution of eravacycline after intravenous multiple dosing to healthy New Zealand White rabbits in male reproductive tissues. All values are expressed as mean ± SEM.

Similar articles

Cited by

References

    1. Zhanel GG, Cheung D, Adam H, Zelenitsky S, Golden A, Schweizer F, Gorityala B, Lagace-Wiens PR, Walkty A, Gin AS, Hoban DJ, Karlowsky JA. 2016. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs 76:567–588. doi:10.1007/s40265-016-0545-8. - DOI - PubMed
    1. Grossman TH, Starosta AL, Fyfe C, O'Brien W, Rothstein DM, Mikolajka A, Wilson DN, Sutcliffe JA. 2012. Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother 56:2559–2564. doi:10.1128/AAC.06187-11. - DOI - PMC - PubMed
    1. Sutcliffe JA, O'Brien W, Fyfe C, Grossman TH. 2013. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother 57:5548–5558. doi:10.1128/AAC.01288-13. - DOI - PMC - PubMed
    1. Xiao XY, Hunt DK, Zhou J, Clark RB, Dunwoody N, Fyfe C, Grossman TH, O'Brien WJ, Plamondon L, Ronn M, Sun C, Zhang WY, Sutcliffe JA. 2012. Fluorocyclines. 1. 7-Fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent. J Med Chem 55:597–605. doi:10.1021/jm201465w. - DOI - PubMed
    1. Livermore DM, Mushtaq S, Warner M, Woodford N. 2016. In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii. Antimicrob Agents Chemother 60:3840–3844. doi:10.1128/AAC.00436-16. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources